{"DataElement":{"publicId":"4889631","version":"1","preferredName":"Patient Chronic Graft Versus Host Disease Post Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based upon an incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor.","longName":"PT_C_GVHD_P_HSCT_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4889630","version":"1","preferredName":"Patient Chronic Graft Versus Host Disease Post Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Usually used to describe a condition that is persistent and long standing._An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Happening at a time subsequent to a reference time; later in time or order._A therapeutic procedure that involves the transplantation of hematopoietic stem cells from a donor to a patient with a myeloid or lymphocytic malignancy._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4889628v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4889628","version":"1","preferredName":"Chronic Graft Versus Host Disease Post Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria","preferredDefinition":"Usually used to describe a condition that is persistent and long standing.:An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:Happening at a time subsequent to a reference time; later in time or order.:A therapeutic procedure that involves the transplantation of hematopoietic stem cells from a donor to a patient with a myeloid or lymphocytic malignancy.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4889628v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic","conceptCode":"C14141","definition":"Usually used to describe a condition that is persistent and long standing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19BF863A-349E-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"ONEDATA","dateModified":"2015-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19BF863A-34AF-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"},{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Does patient have chronic GVH","type":"Preferred Question Text","description":"Does patient have chronic GVHD diagnosed within 3 years after hematopoietic stem cell transplant (HSCT) for any disease, with any graft, and any conditioning regimen with at least one manifestation secondary to fibrosis, including: sclerodermatous skin c. changes, dry mouth, dry eye, esophageal strictures, or vaginal GVHD?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has relapsed after prior stem cell transplantation (SCT), patient has no active GVHD as per treating physician?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have persistent chronic GVHD  manifestations and systemic therapy is indicated?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Does patient have persistent moderate to severe chronic GVHD (cGVHD) per 2014 NIH consensus criteria and received systemic immunosuppressive therapy?","url":null,"context":"COG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"19BF863A-34C7-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"BMAESKE","dateModified":"2022-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}